Founded in 2012, EdisonDx (EDX in China OTC) is a vertically integrated research and development company focused on changing the landscape of diagnosis of Dry eye disease (DED), Cardiovascular diseases and Oncological indications.

NuSep, originated from Australia (NSP in ASX) and now based in Germantown, Maryland, USA, is an innovative biotech company with a mission to develop novel invitro diagnostic platforms based on its nUView rapid protein detection technology. Backed by the 45 years of heritage in the protein discovery, NuSep acquired EdisonDx in 2020, and penetrated into clinical diagnositic market in China.

Dry eye disease, sometimes referred to as dysfunctional tear syndrome, is often a source of frustration for clinicians and patients alike. It can be progressive with major consequences for a patient’s vision and quality of life, yet it remains notoriously underappreciated, misdiagnosed, and undertreated.

Co-developers are building a point-of-care (POCT) laboratory testing system designed to help optometrists and ophthalmologists detect diagnostic-related biomarkers. The company’s TearPRO (http://tearpro.us) provides real-time quantitative results for eye diagnostic tests, enabling eye care physicians to quantify a variety of bio-markers associated with external ocular disorders and treat accordingly.